| Abstract: |
Proton therapy for lung cancer has been demonstrated to have dosimetric advantages over photon therapies in treatment plan comparisons, but the clinical evidence is still relatively limited, as are potential criteria to identify which patients would benefit (or not benefit) from proton therapy. This chapter reviews known indications for passive scattering versus intensity-modulated proton therapy for lung cancer and touches on issues associated with treatment simulation, choice of radiation dose and fractionation schedule, target delineation, treatment verification, and treatment planning for proton therapy. Also discussed are the clinical outcomes of proton therapy for early-stage or locally advanced disease published to date. © 2021 Elsevier Inc. All rights reserved. |
